Home
ALGS
ALGS News

Latest Aligos Therapeutics Inc. (ALGS) News on November 18, 2024

Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Simply Wall St.

8 days ago

Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

11 days ago

Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

GlobeNewswire

11 days ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire

18 days ago

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

GlobeNewswire

a month ago

Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

GlobeNewswire

a month ago

Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

GlobeNewswire

2 months ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Aligos Therapeutics to Present at Investor Conferences in October

GlobeNewswire

2 months ago

Aligos Therapeutics to Present at Investor Conferences in October

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

GlobeNewswire

2 months ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Aligos reports positive data from Phase IIa MASH treatment trial

Clinical Trials Arena

2 months ago

Aligos reports positive data from Phase IIa MASH treatment trial

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

GlobeNewswire

2 months ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

GlobeNewswire

2 months ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks

2 months ago

Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

Zacks

3 months ago

How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

MT Newswires

3 months ago

Aligos Therapeutics to Implement 1-for-25 Reverse Stock Split; Shares Fall

Aligos Therapeutics Announces Reverse Stock Split

GlobeNewswire

3 months ago

Aligos Therapeutics Announces Reverse Stock Split

What Makes Aligos Therapeutics (ALGS) a New Buy Stock

Zacks

3 months ago

What Makes Aligos Therapeutics (ALGS) a New Buy Stock

Aligos Therapeutics Strengthens Board with Two New Independent Directors

GlobeNewswire

3 months ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Aligos Therapeutics Second Quarter 2024 Earnings: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023)

Simply Wall St.

3 months ago

Aligos Therapeutics Second Quarter 2024 Earnings: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023)

Hepatitis B market is ripe for treatment development, says Aligos CEO

Pharmaceutical Technology

3 months ago

Hepatitis B market is ripe for treatment development, says Aligos CEO

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results

Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire

4 months ago

Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024

Companies Like Aligos Therapeutics (NASDAQ:ALGS) Could Be Quite Risky

Simply Wall St.

4 months ago

Companies Like Aligos Therapeutics (NASDAQ:ALGS) Could Be Quite Risky

MT Newswires

4 months ago

Aligos Therapeutics Collaborating With Xiamen Amoytop Biotech in China for Chronic Hepatitis B Patients

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

GlobeNewswire

4 months ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

GlobeNewswire

4 months ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection

Zacks

5 months ago

AbbVie (ABBV) Parkinson's Candidate Faces 2nd FDA Rejection

GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance

Zacks

5 months ago

GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance

J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease

Zacks

5 months ago

J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease

AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer

Zacks

5 months ago

AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer

Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold

Zacks

5 months ago

Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold

AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

Zacks

5 months ago

AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

5 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller

AFP

5 months ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up

AFP

5 months ago

Italy beat Bosnia in final Euros warm-up

Macron Calls French Legislative Election After Far-Right Surge

Bloomberg

5 months ago

Macron Calls French Legislative Election After Far-Right Surge

Trump loyalists proud to support 'felon' at Las Vegas rally

AFP

5 months ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

5 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

5 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

5 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

GlobeNewswire

5 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now

Zacks

5 months ago

Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

GlobeNewswire

6 months ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

GlobeNewswire

6 months ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)

Zacks

6 months ago

After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)

Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)

Simply Wall St.

6 months ago

Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

GlobeNewswire

6 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire

7 months ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

GlobeNewswire

7 months ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

GlobeNewswire

7 months ago

Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

GlobeNewswire

7 months ago

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

GlobeNewswire

7 months ago

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

8 months ago

Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

GlobeNewswire

8 months ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

GlobeNewswire

8 months ago

Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects

Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

8 months ago

Aligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

8 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

GlobeNewswire

8 months ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

GlobeNewswire

9 months ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

GlobeNewswire

9 months ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

GlobeNewswire

9 months ago

Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

Simply Wall St.

10 months ago

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

D-Wave Quantum to Present at 26th Annual Needham Growth Conference

NewMediaWire

10 months ago

D-Wave Quantum to Present at 26th Annual Needham Growth Conference

Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?

Zacks

10 months ago

Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?

Those who invested in Abeona Therapeutics (NASDAQ:ABEO) a year ago are up 98%

Simply Wall St.

a year ago

Those who invested in Abeona Therapeutics (NASDAQ:ABEO) a year ago are up 98%

Expensify Adds Budgeting to Help Companies Prepare for 2024

Business Wire

a year ago

Expensify Adds Budgeting to Help Companies Prepare for 2024

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds

Business Wire

a year ago

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds

GlobeNewswire

a year ago

Diamond Equity Research Releases Update Note on QuantaSing Group Limited (NASDAQ: QSG)

A Closer Look At QuantaSing Group Limited's (NASDAQ:QSG) Impressive ROE

Simply Wall St.

a year ago

A Closer Look At QuantaSing Group Limited's (NASDAQ:QSG) Impressive ROE

After losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gain

Simply Wall St.

a year ago

After losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gain

Investors in Ribbon Communications (NASDAQ:RBBN) have unfortunately lost 65% over the last three years

Simply Wall St.

a year ago

Investors in Ribbon Communications (NASDAQ:RBBN) have unfortunately lost 65% over the last three years

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

GlobeNewswire

a year ago

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

GlobeNewswire

a year ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Yatra Online, Aramco Asia Join Hands to Address Regional Travel Demand

PR Newswire

a year ago

Yatra Online, Aramco Asia Join Hands to Address Regional Travel Demand

13 Stocks Insiders are Buying Now

Insider Monkey

a year ago

13 Stocks Insiders are Buying Now

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

Zacks

a year ago

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

GlobeNewswire

a year ago

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

B. Riley Financial, Inc. Bolsters Position in Babcock & Wilcox Enterprises Inc

GuruFocus.com

a year ago

B. Riley Financial, Inc. Bolsters Position in Babcock & Wilcox Enterprises Inc

UPDATE: ICZOOM to Present at Benchmark Company's Annual Investor Conference

PR Newswire

a year ago

UPDATE: ICZOOM to Present at Benchmark Company's Annual Investor Conference

South China Morning Post

a year ago

Lufax to acquire Hong Kong virtual lender Ping An OneConnect Bank for US$119.5 million

OneConnect Announces Third Quarter and Nine Months Ended September 30, 2023 Unaudited Financial Results

PR Newswire

a year ago

OneConnect Announces Third Quarter and Nine Months Ended September 30, 2023 Unaudited Financial Results

GlobeNewswire

a year ago

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

GlobeNewswire

a year ago

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Thomson Reuters StreetEvents

a year ago

Q1 2024 Matrix Service Co Earnings Call

Applied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ...

GuruFocus.com

a year ago

Applied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ...

Associated Press Finance

a year ago

Matrix Service: Fiscal Q1 Earnings Snapshot

Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)

GlobeNewswire

a year ago

Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)

Allurion to Participate in the Jefferies London Healthcare Conference

Business Wire

a year ago

Allurion to Participate in the Jefferies London Healthcare Conference

Share on Social Networks: